MZMartin Zenker

Martin Zenker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Martin Zenker has a total of 96 co-authors. Here are the top co-authors by number of shared publications:

  • André Reis

    Institute of Human Genetics, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

    3 shared publications
  • Anita Rauch

    Institute of Medical Genetics, University of Zurich, Schlieren, Zurich, Switzerland

    3 shared publications
  • Christian P Kratz

    15Department of Pediatrics and Adolescent Medicine, University of Freiburg, Freiburg, Germany

    2 shared publications
  • Ineke van der Burgt

    Department of Human Genetics, University Medical Center St Radboud, Nijmegen, The Netherlands

    2 shared publications
  • Udo Trautmann

    Institute of Human Genetics, Friedrich‐Alexander‐University Erlangen‐Nuremberg, Erlangen, Germany

    2 shared publications
  • Verena Matejas

    Institute of Human Genetics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Germany

    2 shared publications

Latest Publications

  • Craniosynostosis in patients with Noonan syndrome caused by germline KRAS mutations

    by Christian P. Kratz, Giuseppe Zampino, Marjolein Kriek, Sarina G. Kant, Chiara Leoni, Francesca Pantaleoni, Anne Marie Oudesluys‐Murphy, Concezio Di Rocco, Stephan P. Kloska, Marco Tartaglia, et al.

    Craniosynostosis, the premature fusion of one or more cranial sutures, is a developmental defect that disrupts the cranial morphogenetic program, leading to variable dysmorphic craniofacial features and associated functional abnormalities. Craniosynostosis is frequently observed as an associated feature in a number of clinically and genetically heterogeneous syndromic conditions, including a group of disorders caused by activating mutations in genes coding for the fibroblast growth factor receptor family members FGFR1, FGFR2, and FGFR3. In these disorders, dysregulation of intracellular signaling promoted by the aberrant FGFR function is mediated, at least in part, by the RAS‐MAPK transduction pathway. Mutations in KRAS, HRAS, and other genes coding for proteins participating in this signaling cascade have recently been identified as underlying Noonan syndrome (NS) and related disorders. While cardinal features of these syndromes include distinctive dysmorphic facial features, reduced growth, congenital heart defects, and variable ectodermal anomalies and cognitive impairment, craniosynostosis is not a recognized feature. Here, we report on the occurrence of premature closure of cranial sutures in subjects with NS, and their specific association with mutations in the KRAS gene. These findings highlight the pathogenetic significance of aberrant signaling mediated by the RAS signaling pathway in other known forms of craniosynostosis, and suggest that, even in the absence of radiologically demonstrable synostosis of the calvarian sutures, dysregulated growth and/or suture closure at specific craniofacial sites might contribute to the craniofacial anomalies occurring in NS.


  • Fraser syndrome due to homozygosity for a splice site mutation of FREM2

    by Yousef Shafeghati, Andrea Kniepert, Ghazal Vakili, Martin Zenker


  • Mutation and phenotypic spectrum in patients with cardio‐facio‐cutaneous and Costello syndrome

    by AL Schulz, B Albrecht, C Arici, I Van Der Burgt, A Buske, G Gillessen‐Kaesbach, R Heller, D Horn, Ca Hübner, Gc Korenke, et al.

    Cardio‐facio‐cutaneous (CFC) and Costello syndrome (CS) are congenital disorders with a significant clinical overlap. The recent discovery of heterozygous mutations in genes encoding components of the RAS–RAF–MAPK pathway in both CFC and CS suggested a similar underlying pathogenesis of these two disorders. While CFC is heterogeneous with mutations in BRAF, MAP2K1, MAP2K2 and KRAS, HRAS alterations are almost exclusively associated with CS. We carried out a comprehensive mutation analysis in 51 CFC‐affected patients and 31 individuals with CS. Twelve different BRAF alterations were found in twenty‐four patients with CFC (47.0%), two MAP2K1 mutations in five (9.8%) and two MAP2K2 sequence variations in three CFC‐affected individuals (5.9%), whereas three patients had a KRAS alteration (5.9%). We identified four different missense mutations of HRAS in twenty‐eight cases with CS (90.3%), while KRAS mutations were detected in two infants with a phenotype meeting criteria for CS (6.5%). In 14 informative families, we traced the parental origin of HRAS alterations and demonstrated inheritance of the mutated allele exclusively from the father, further confirming a paternal bias in the parental origin of HRAS mutations in CS. Careful clinical evaluation of patients with BRAF and MAP2K1/2 alterations revealed the presence of slight phenotypic differences regarding craniofacial features in MAP2K1‐ and MAP2K2‐mutation positive individuals, suggesting possible genotype–phenotype correlations.


  • SOS1 is the second most common Noonan gene but plays no major role in cardio-facio-cutaneous syndrome

    by Martin Zenker, Denise Horn, Dagmar Wieczorek, Judith Allanson, Silke Pauli, Ineke van der Burgt, Helmuth-Guenther Doerr, Harald Gaspar, Michael Hofbeck, Gabriele Gillessen-Kaesbach, et al.

    Background: Heterozygous gain-of-function mutations in various genes encoding proteins of the Ras-MAPK signalling cascade have been identified as the genetic basis of Noonan syndrome (NS) and cardio-facio-cutaneous syndrome (CFCS). Mutations of SOS1, the gene encoding a guanine nucleotide exchange factor for Ras, have been the most recent discoveries in patients with NS, but this gene has not been studied in patients with CFCS. Methods and results: We investigated SOS1 in a large cohort of patients with disorders of the NS–CFCS spectrum, who had previously tested negative for mutations in PTPN11, KRAS, BRAF, MEK1 and MEK2. Missense mutations of SOS1 were discovered in 28% of patients with NS. In contrast, none of the patients classified as having CFCS was found to carry a pathogenic sequence change in this gene. Conclusion: We have confirmed SOS1 as the second major gene for NS. Patients carrying mutations in this gene have a distinctive phenotype with frequent ectodermal anomalies such as keratosis pilaris and curly hair. However, the clinical picture associated with SOS1 mutations is different from that of CFCS. These findings corroborate that, despite being caused by gain-of-function mutations in molecules belonging to the same pathway, NS and CFCS scarcely overlap genotypically.


  • Myopathy caused by HRAS germline mutations: implications for disturbed myogenic differentiation in the presence of constitutive HRas activation

    by Ineke van der Burgt, William Kupsky, Stephani Stassou, Ali Nadroo, Cândida Barroso, Angelika Diem, Christian P Kratz, Radovan Dvorsky, Mohammad Reza Ahmadian, Martin Zenker

    Background: Rare reports on patients with congenital myopathy with excess of muscle spindles (CMEMS), hypertrophic cardiomyopathy and variable features resembling Noonan syndrome have been published, but the genetic basis of this condition is so far unknown. Methods and results: We analysed PTPN11 and RAS genes in five unrelated patients with this phenotype, and found HRAS mutations in four of them. Two disease-associated mutations, G12V and G12S, have previously been observed in patients with Costello syndrome (CS), and two other mutations, E63K and Q22K, are novel. All four mutations are predicted to enhance downstream HRas signalling, suggesting that CMEMS is a developmental consequence of sustained HRas activation in skeletal muscle. Conclusion: This type of myopathy may represent a previously unrecogned manifestation of CS. However, some patients carrying HRAS mutations may exhibit prominent congenital muscular dysfunction, although features of CS may be less obvious, suggesting that germline HRAS mutations may underlie some cases of otherwise unclassified neonatal neuromuscular disorders.


  • Fraser and Ablepharon macrostomia phenotypes: Concurrence in one family and association with mutatedFRAS1

    by Denise Pontes Cavalcanti, Verena Matejas, Daniela Luquetti, Marcos Fernando Mello, Martin Zenker

    To date, Fraser syndrome (FS) and Ablepharon macrostomia syndrome (AMS) have been considered distinct disorders, but they share strikingly similar patterns of congenital abnormalities, specifically craniofacial anomalies. While recent research has led to the identification of the genes FRAS1 and FREM2 as the cause of FS, the genetic basis of AMS continues to be enigmatic. We report on the concurrence of AMS‐like and Fraser phenotypes in a Brazilian family. Both affected sibs were homozygous for a novel splice site mutation in the FRAS1 gene. Extensive studies on mRNA expression indicated that this mutation most likely leads to loss of function as most previously reported FRAS1 mutations associated with FS. We conclude that a phenotype resembling AMS is a rare clinical expression of FS with no obvious genotype–phenotype correlation. However, the molecular basis of “true” AMS which has been reported as a sporadic disorder in all cases but one, and so far with no relation to FS, is probably different and still needs to be further investigated.


  • A male infant with a 9.6 Mb terminal Xp deletion including the OA1 locus: Limit of viability of Xp deletions in males

    by Volker O. Melichar, Sabine Guth, Heide Hellebrand, Alfons Meindl, Katharina von der Hardt, Cornelia Kraus, Udo Trautmann, Wolfgang Rascher, Anita Rauch, Martin Zenker

    Males with deletions of or within Xp22.3‐pter display variable contiguous gene syndromes including manifestations of Léri‐Weill syndrome, chondrodysplasia punctata, mental retardation, ichthyosis, Kallmann syndrome, and ocular albinism. Herein, we report on a male infant with a large, cytogenetically visible, terminal Xp deletion defined by extensive FISH and STS marker analysis to encompass 9.6 Mb, and findings of all of the disorders mentioned above. His deletion approximates the largest Xp terminal deletion ever reported in a male individual. Since the extent of terminal Xp deletions viable in males is limited by the position of male lethal genes in Xp22.2 at about 10–11 Mb from the telomere, this patient falls into the category of the most severe male terminal Xp deletion phenotype.


  • Genotype–epigenotype–phenotype correlations in females with frontometaphyseal dysplasia

    by Martin Zenker, Lutz Nährlich, Heinrich Sticht, André Reis, Denise Horn

    Frontometaphyseal dysplasia (FMD) belongs to a group of overlapping skeletal dysplasias, the common molecular basis of which are mutations of FLNA, the gene encoding filamin A. The nature of the mutation has been considered the major determinant of the phenotype within this group that comprises the otopalatodigital syndromes (OPD1, OPD2) and Melnick–Needles syndrome besides FMD. However, to date the molecular pathomechanisms are not well understood. In FMD only few FLNA mutations have been reported which do not cluster in a specific region of the protein. We report on a novel de novo mutation 5182G → T in exon 31 of the FLNA gene in a girl with manifestations of FMD and OPD1. This mutation is predicted to lead to the exchange of a highly conserved glycine residue at position 1,728 by cysteine (G1728C) in repeat 15 of the filamin A rod domain. In a second family with FMD, we identified a known mutation (S1186L) in a mother and her son. In contrast to most previous reports on manifesting females or carriers of the FLNA‐related skeletal dysplasias, the affected females presented here showed only mild to moderate skewing of X‐inactivation against the mutant allele. Our data may indicate that in females, genotype–phenotype correlation between certain FLNA mutations and OPD1 and FMD, respectively, is less strict than previously assumed. We propose that X‐inactivation is an important epigenetic modifier of the phenotype in females with the FLNA‐related skeletal dysplasias.


  • Severe, neonatal‐onset OTC deficiency in twin sisters with a de novo balanced reciprocal translocation t(X;5)(p21.1;q11)

    by Martin Zenker, Bendicht Wermuth, Udo Trautmann, Ina Knerr, Cornelia Kraus, Anita Rauch, André Reis

    OTC deficiency, the most common urea cycle defect, is transmitted as a partially dominant X‐linked trait. The most severe form of the disease, however, is usually restricted to males. We report on monozygotic female twins with severe neonatal‐onset OTC deficiency and a de novo balanced reciprocal translocation t(X;5)(p21.1;q11). Disruption of the OTC gene on the derivative X‐chromosome was confirmed by FISH analysis. Consistent inactivation of the normal X could be demonstrated by RGB staining. Manifestation of X‐linked recessive disorders in females due to a balanced reciprocal X‐autosome translocation has previously been described in Duchenne muscular dystrophy and several other disorders but not in OTC deficiency. This report emphasizes the importance of chromosome analysis in any female manifesting severe OTC deficiency.


  • Congenital nephrosis, mesangial sclerosis, and distinct eye abnormalities with microcoria: An autosomal recessive syndrome

    by Martin Zenker, Tim Tralau, Thomas Lennert, Susanne Pitz, Karlheinz Mark, Henry Madlon, Jörg Dötsch, André Reis, Horst Müntefering, Luitgard M. Neumann

    We observed the occurrence of congenital nephrotic syndrome (CNS) and distinct ocular anomalies in two unrelated families. Eleven children from both families presented with a similar course of renal disease starting with nephrotic syndrome and renal failure prenatally or immediately after birth that resulted in death before the age of 2 months. Kidney histopathology showed diffuse mesangial sclerosis (DMS). Clinically obvious eye abnormalities were recognized in six of the eight patients in whom sufficient clinical data were available. Ocular anomalies included enlarged or large appearing corneae in some cases suggesting buphthalmos, and extremely narrow, nonreactive pupils (microcoria). Pathological examination of the eyes of two aborted fetuses revealed a more complex ocular maldevelopment including posterior lenticonus as well as anomalies of cornea and retina. On the basis of these observations and other cases in the literature, we delineate a previously unrecognized distinct entity characterized by congenital nephrotic syndrome, DMS, and eye abnormalities with microcoria as the leading clinical feature. Pedigrees of affected families with parental consanguinity support autosomal recessive inheritance. We propose that this syndrome should be designated microcoria‐congenital nephrosis syndrome or Pierson syndrome. Possible overlap with Galloway–Mowat syndrome and relations to other oculo‐renal syndromes are discussed.